From: TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer
IHC Scoring | P-value | ||||
---|---|---|---|---|---|
Negative expression (0) | Weak expression (2–4) | Moderate expression (5–6) | Strong expression (7–8) | ||
When sensitive to cisplatin (n = 20) | 0 | 9 | 7 | 4 | P < 0.001 |
After resistant to cisplatin (n = 20) | 0 | 0 | 3 | 17 |